While the majority of current therapeutic interventions for AD primarily target Aβ and tau directly, one critical research challenge is to determine whether enhancement of brain endogenous clearance pathways could be also a therapeutic strategy. The gene discussed is MAPT; the disease is Alzheimer disease.